

Study Number:	AALL0631			
NCT #:	NCT00557193			
Dataset #:	D1			
PMID #:	33623141			
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
Variable Number	Variable Name	Variable Type	Label	Notes
1	USI	char	Unique patient identifier	
2	studyID	char	Study ID	
3	eligible	num	Eligibility for AALL0631	1=eligible; 0=ineligible
4	post_ind	num	Evaluable for Post Induction	1=evaluable for post induction; 0=inevaluable for post induction
5	treatmentID	num	Treatment ID	10="Induction" 20="Arm A"; 30="Arm B"; 40="Arm C"; 43="Arm C: S/A, 3.5 mg"; 44="Arm C: S/A, 4.0 mg"; 45="Arm C: S/A, 4.25 mg"; 46="Arm C: S/A, 5.0 mg"
6	ot_reason_ind	char	Off therapy Reason (Induction)	
7	ot_reason_post_ind	char	Off therapy Reason (Post Induction)	
8	riskgrp	char	Risk group	"SR"; "IR"; "HR"
9	rand	char	Randomization	"Arm A"; "Arm B: S/A phase"; "Arm B: Randomized"; "Arm C: S/A phase"; "Arm C: Randomized"; "Arm C: Assigned"
10	arm	char	Treatment Arm group 1	"Arm A"; "Arm B"; "Arm C"

Study Number:	AALL0631			
NCT #:	NCT00557193			
Dataset #:	D1			
PMID #:	33623141			
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
11	arm1	char	Treatment Arm group 2	“Arm A”; “Arm B”; “Arm C at DL1”; “Arm C at DL2”; “Arm C at Efficacy”
12	arm2	char	Treatment Arm group 3	“Arm A”; “Arm B”; “Arm C at DL1”; “Arm C at DL2”
13	MLL	char	MLL group	“MLL-G”; “MLL-R”
14	group	char	KMTR2A group	“KMT2A-g”; “KMT2A-r”
15	WBC	num	White Blood Cell values	10 ⁹ /L
16	Sex	char	gender	
17	cns_catg	char	CNS status	“CNS1”; “CNS2”; “CNS3”; “Unknown”
18	race	char	Race group	“White”; “Non-White”; “Unknown”
19	ethnicity	char	Ethnic group	“Hispanic or Latino”; “Not Hispanic or Latino”; “Unknown”
20	age_dia	num	Age at diagnosis	days
21	PIA	char	Mean FLT3 inhibition (from up to 5 protocol-defined collections)	Percent N/A=“Not Applicable”; nd=“No Data”
22	EVS	num	Mean ex vivo sensitivity (from technical triplicate)	

Study Number:	AALL0631			
NCT #:	NCT00557193			
Dataset #:	D1			
PMID #:	33623141			
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
23	r_partner	char	KMT2A Partner	“AFF1”; “MLLT1”; “MLLT10”; “MLT3”; “Other” “Unknown”
24	Immunophenotype	char	Immunophenotype	“B-ALL”; “Other”
25	event	char	Type of first EFS event	“Death”; “Relapse”; “Treatment_failure”
26	relapse_site_c	char	Relapse site group	“BM”; “IEM”
27	relapse_site_str	char	Relapse site detail group	“cBM + CNS”; “cBM + Skin”; “cBM + Test”; “iBM”; “iCNS”; “iSkin”; “other”
28	event_duration	char	Timing of first EFS event	“Induction”; “Remission/on protocol”; “Remission/off protocol”
29	death_AE	char	Death AE events if death is first EFS event	“Aneurysm”; “Infx”; “Neuro”; “TRM”
30	evaluable_remission	char	Evaluable for remission at end of Induction Intensification	“Yes”
31	remission	char	Remission at end of Induction Intensification	“Yes”; “No”
32	EFSX1	num	EFS censor status	1=had event; 0=censored

Study Number:	AALL0631			
NCT #:	NCT00557193			
Dataset #:	D1			
PMID #:	33623141			
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
33	EFSX2	num	Event-free survival (EFS) time in days from start of induction	
34	OSX1	num	OS censor status	1=had event; 0=censored
35	OSX2	num	Overall survival (OS) time in days from start of induction	
36	DFSX1	num	DFS censor status	1=had event; 0=censored
37	DFSX2	num	Disease-free survival (DFS) time in days from start of induction intensification	
38	ODSX1	num	OS censor status (same clocking time with DFS)	1=had event; 0=censored
39	ODSX2	num	Overall survival (OS) time in days (same clocking time with DFS)	
40	x1	num	Event-free survival (EFS) time in days	variables for the cumulative incidence for Risk Group in Figure 2
41	cat1	char	Risk Group	“IR”; “HR” variables for the cumulative incidence for Risk Group in Figure 2
42	ci_cat1	num	Failure Event	0=“None”; 1=“Relapse and TF”; 2=“Death”; variables for the cumulative incidence for Risk Group in Figure 2
43	ccr_x1	num	Disease-free survival (DFS) time in days	variables for the cumulative incidence for treatment arm in Figure 3

Study Number:	AALL0631			
NCT #:	NCT00557193			
Dataset #:	D1			
PMID #:	33623141			
Comments:	Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
44	cat2	char	Treatment Arm	“Arm B”; “Arm C at DL2” variables for the cumulative incidence for treatment arm in Figure 3
45	ci_cat2	num	Failure Event	0=“None”; 1=“Relapse and TF”; 2=“Death”; variables for the cumulative incidence for treatment arm in Figure 3
46	SCT	char	Received Stem Cell Transplant (SCT) in first remission	“Yes”, “No”
47	eval_remission_EOI	char	Evaluable for remission at end of Induction	“Yes”, “No”
48	remission_EOI	char	Remission at end of Induction	“Yes”, “No”